STOCK TITAN

BullFrog AI Announces Participation at AACR Annual Meeting

(Neutral)
Tags
AI

BullFrog AI (NASDAQ: BFRG) will exhibit at the American Association for Cancer Research Annual Meeting 2026 in San Diego from April 17-22, showcasing its end-to-end AI-driven drug discovery and development workflow at booth 2957.

Company representatives will be available for meetings and inquiries; contact Steven Seegers for scheduling.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – BFRGW

-5.81%
-5.81% Session close to close

In the Apr 14 session, BFRGW declined 5.81%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.8% in the session following this news. A negative reaction despite neutral or mod...
Analysis

The stock moved -5.8% in the session following this news. A negative reaction despite neutral or modestly positive news fits prior patterns where some AI-tagged updates were followed by selloffs, even on constructive platform developments. Filings highlighting constrained liquidity and past Nasdaq equity compliance concerns may have kept focus on balance sheet risk. Against that backdrop, even seemingly routine conference participation headlines could have been used as liquidity events rather than sustained catalysts.

Key Figures

Conference dates: April 17-22, 2026 Booth number: 2957
2 metrics
Conference dates April 17-22, 2026 AACR Annual Meeting schedule
Booth number 2957 BullFrog AI exhibitor booth at AACR 2026

Previous AI Reports

5 past events · Latest: Mar 30 (Positive)
Same Type Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Mar 30 Commercial AI agreement Positive +38.4% Commercial deal with top-5 pharma using bfLEAP for MDD targets.
Mar 25 Platform launch Positive +0.0% Unveiling bfARENAS decision engine for R&D and trial strategy.
Mar 11 Webinar announcement Positive +37.2% Webinar to introduce precision AI decision engine for portfolios.
Feb 04 Capability preview Positive -5.2% Advance notice of new scenario-based AI engine launch date.
Jan 27 White paper release Neutral -8.3% White paper on data harmonization and bfPREP AI-ready datasets.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-related announcements have often produced sizable, but mixed, price reactions, with both sharp gains and notable selloffs.

Recent Company History

Over the last few months, BullFrog AI has issued a series of AI-focused updates: platform enhancements, webinars, and a commercial agreement with a top-5 pharma partner. These ranged from a data harmonization white paper (Jan 27) to unveiling a scenario engine and then securing an MDD collaboration on Mar 30. Price reactions have alternated between strong gains and pullbacks, indicating that similar AI/platform news can drive volatility but not always in the same direction.

Key Terms

artificial intelligence, machine learning, biomedical data, oncology, +1 more
5 terms
artificial intelligence technical
"a technology company using artificial intelligence (“AI”) and machine learning"
Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.
machine learning technical
"using artificial intelligence (“AI”) and machine learning to turn complex biomedical data"
Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.
View in glossary
biomedical data medical
"machine learning to turn complex biomedical data into actionable insights"
Biomedical data are information about human health collected from tests, devices, medical records, lab results, genetic analyses, or patient sensors. Investors care because this information drives product development, regulatory approval, and clinical value—think of it as the fuel that shows whether a medical idea actually works and is safe; better, verifiable data can speed approvals, reduce risk, and increase a company’s commercial potential.
oncology medical
"breakthroughs in oncology. Showcasing top-tier research from around the world"
Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.
clinical trials medical
"from basic biology and prevention to clinical trials and patient advocacy"
Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957

GAITHERSBURG, Md., April 14, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2026. The AACR Annual Meeting will be held from April 17-22 at the San Diego Convention Center in San Diego, California.

Companies, researchers, and other conference attendees who are interested in meeting with the BullFrog AI team should visit booth 2957 or contact Steven Seegers at steven.seegers@bullfrogai.com.

The AACR Annual Meeting is the premier gathering for the global cancer community, uniting researchers, clinicians, patients, and advocates to share cutting-edge breakthroughs in oncology. Showcasing top-tier research from around the world, the event covers the entire spectrum of cancer care, from basic biology and prevention to clinical trials and patient advocacy. With a theme this year of “Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally,” the meeting will highlight the work of the best minds in cancer science and medicine from institutions all over the world.

About BullFrog AI

BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors:
CORE IR
ir@bullfrogai.com

Media:
CORE PR
pr@bullfrogai.com


FAQ

When and where will BullFrog AI (BFRG) exhibit at AACR Annual Meeting 2026?

BullFrog AI will exhibit at the AACR Annual Meeting in San Diego April 17-22, 2026. According to BullFrog AI, the company will staff booth 2957 to discuss its AI-driven drug discovery and development workflow with attendees and researchers.

What will BullFrog AI (BFRG) present at booth 2957 during AACR 2026?

BullFrog AI will present its end-to-end AI and machine-learning drug discovery workflow at booth 2957. According to BullFrog AI, the team will discuss how it turns complex biomedical data into actionable insights for oncology research and development.

How can investors or researchers meet BullFrog AI (BFRG) team at AACR 2026?

Attendees can visit booth 2957 or contact Steven Seegers to schedule meetings during April 17-22. According to BullFrog AI, emailing steven.seegers@bullfrogai.com is the recommended way to arrange discussions with company representatives.

Does BullFrog AI (BFRG) focus on oncology at the AACR Annual Meeting 2026?

Yes. BullFrog AI will focus on oncology-related applications of its AI tools at AACR 2026. According to BullFrog AI, the company will highlight use cases for translating complex cancer biology data into actionable insights for drug discovery and development.

Is the AACR Annual Meeting 2026 important for BullFrog AI (BFRG) business development?

The AACR meeting offers networking and visibility for oncology innovators like BullFrog AI. According to BullFrog AI, exhibiting at AACR allows the company to engage researchers, clinicians, and potential partners around its AI-driven drug discovery capabilities.

What are the dates and venue for AACR Annual Meeting 2026 where BFRG will attend?

AACR Annual Meeting 2026 runs April 17-22 at the San Diego Convention Center. According to BullFrog AI, the company will be onsite throughout the event to meet attendees at booth 2957.